Literature DB >> 19935727

Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source.

P Chevallier1, I Hebia-Fellah, L Planche, T Guillaume, C Bressolette-Bodin, M Coste-Burel, F Rialland, M Mohty, B-M Imbert-Marcille.   

Abstract

Occurrence of CMV, EBV and human herpes virus 6 (HHV6) infections and immune reconstitution were compared in 15 adult patients receiving a cord blood transplantation (CBT) and 40 patients who received an allogeneic transplantation from a matched unrelated donor (MUD). Herpes virus DNA quantifications in the blood (459 samples) were performed before and then monthly up to 9 months after transplant and the main lymphocytes populations were counted at 3, 6 and 9 months. Incidence of HHV6 infection was significantly higher in the CBT group (80 vs 42.5%; P<0.0001), with higher viral load (P<0.0001). In multivariate analysis, the use of a CBT and a myeloablative conditioning regimen were found to increase the risk of HHV6 infection (odds ratio (OR)=5.4, P=0.02 and OR=3.5, P=0.04, respectively). Incidences of CMV were similar between the two groups whereas MUD increased the risk of EBV infection, in univariate analysis only. HHV6 reactivation translated toward delayed neutrophils and plts engraftment in the two groups. MUD and CBT do not share the same immune reconstitution patterns, notably for B and CD8 lymphocytes and NK cells. There is a strong and specific relationship between HHV6 infection and the use of cord blood cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19935727     DOI: 10.1038/bmt.2009.326

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  28 in total

1.  High human herpesvirus 6 viral load in pediatric allogeneic hematopoietic stem cell transplant patients is associated with detection in end organs and high mortality.

Authors:  Lena E Winestone; Rajesh Punn; John S Tamaresis; Julia Buckingham; Benjamin A Pinsky; Jesse J Waggoner; Sandhya Kharbanda
Journal:  Pediatr Transplant       Date:  2017-11-27

2.  First-Onset Herpesviral Infection and Lung Injury in Allogeneic Hematopoietic Cell Transplantation.

Authors:  Xiaofeng Zhou; David N O'Dwyer; Meng Xia; Holly K Miller; Paul R Chan; Kelsey Trulik; Mathew M Chadwick; Timothy C Hoffman; Camille Bulte; Kevin Sekerak; Carol A Wilke; Swapneel J Patel; Wayne M Yokoyama; Susan Murray; Gregory A Yanik; Bethany B Moore
Journal:  Am J Respir Crit Care Med       Date:  2019-07-01       Impact factor: 21.405

3.  Risk factors of clinically refractory CMV reactivation following allogeneic HSCT: a single-center study in China.

Authors:  X Bao; Q Zhu; S Xue; Y Xu; X Ma; F Chen; X Hu; Z Zhu; S Chen; A Sun; D Wu; Y Song; H Qiu
Journal:  Bone Marrow Transplant       Date:  2016-10-17       Impact factor: 5.483

4.  The impact of CD34+ cell dose on engraftment after SCTs: personalized estimates based on mathematical modeling.

Authors:  T Stiehl; A D Ho; A Marciniak-Czochra
Journal:  Bone Marrow Transplant       Date:  2013-09-23       Impact factor: 5.483

5.  Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation.

Authors:  Doris M Ponce; Junting Zheng; Anne Marie Gonzales; Marissa Lubin; Glenn Heller; Hugo Castro-Malaspina; Sergio Giralt; Katharine Hsu; Ann A Jakubowski; Robert R Jenq; Guenther Koehne; Esperanza B Papadopoulos; Miguel A Perales; Marcel R van den Brink; James W Young; Farid Boulad; Nancy A Kernan; Rachel Kobos; Susan Prockop; Andromachi Scaradavou; Trudy Small; Richard J O'Reilly; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-11       Impact factor: 5.742

6.  Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure.

Authors:  Troy C Lund; Jessica Liegel; Nelli Bejanyan; Paul J Orchard; Qing Cao; Jakub Tolar; Claudio Brunstein; John E Wagner; Michael R Verneris; Daniel Weisdorf
Journal:  Am J Hematol       Date:  2015-10       Impact factor: 10.047

7.  An Animal Model That Mimics Human Herpesvirus 6B Pathogenesis.

Authors:  Bochao Wang; Yasuyuki Saito; Mitsuhiro Nishimura; Zhenxiao Ren; Lidya Handayani Tjan; Alaa Refaat; Rie Iida-Norita; Ryuko Tsukamoto; Masato Komatsu; Tomoo Itoh; Takashi Matozaki; Yasuko Mori
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

8.  Cytomegalovirus induces strong antileukemic effect in acute myeloid leukemia patients following sibling HSCT without ATG-containing regimen.

Authors:  Xiebing Bao; Qian Zhu; Shengli Xue; Xiaohui Hu; Xiao Ma; Feng Chen; Suning Chen; Aining Sun; Depei Wu; Jianhua Yu; Xiaojin Wu; Huiying Qiu
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

9.  Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin.

Authors:  Craig Sauter; Michelle Abboud; Xiaoyu Jia; Glenn Heller; Anne-Marie Gonzales; Marissa Lubin; Rebecca Hawke; Miguel-Angel Perales; Marcel R van den Brink; Sergio Giralt; Genovefa Papanicolaou; Andromachi Scaradavou; Trudy N Small; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2011-03-01       Impact factor: 5.742

10.  Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin.

Authors:  Amanda L Olson; Parastoo B Dahi; Junting Zheng; Sean M Devlin; Marissa Lubin; Anne Marie Gonzales; Sergio A Giralt; Miguel-Angel Perales; Esperanza B Papadopoulos; Doris M Ponce; James W Young; Nancy A Kernan; Andromachi Scaradavou; Richard J O'Reilly; Trudy N Small; Genovefa Papanicolaou; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-16       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.